Skip to content

Comparison of ketamine and dexmedetomidine in maintenance anesthesia

Comparison of Ketamine and Dexmedetomidine in Maintenance of Anesthesia with Bispectral Index Scale during General Anesthesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210415050976N5
Enrollment
90
Registered
2021-06-22
Start date
2021-09-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia. Generalized tularemia

Interventions

Intervention 1: Intervention group 1: Dexmedetomidine infusion dose of 0.5 to 1 macro / kg body weight per hour will be administered during general anesthesia. The drug dexmedetomidine is used under t

Sponsors

Jahrom University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Being an NPO for 8 hours ASA class one or two Satisfaction with general anesthesia

Exclusion criteria

Exclusion criteria: High blood pressure Severe cardiovascular disease Severe dysfunction of the liver and kidneys

Design outcomes

Primary

MeasureTime frame
Depth of anesthesia. Timepoint: After induction of anesthesia by an observer until the end of anesthesia will continue every 15 minutes. Method of measurement: Cerebral State Monitor device made by Donmeter.dk company from Denmark and electrocardiographic electrodes will be used.

Secondary

MeasureTime frame
The pain. Timepoint: After surgery in recovery. Method of measurement: Pain is assessed according to the ruler criteria.;Frequent nausea and vomiting. Timepoint: In recovery. Method of measurement: Based on the frequency of nausea and vomiting.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Kalani

Jahrom University of Medical Sciences

k.navid@jums.ac.ir+98 71 2536 5231

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026